Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
August 13, 2024 17:37 ET
|
Calidi Biotherapeutics, Inc
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment...
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
July 29, 2024 09:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
July 18, 2024 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
July 16, 2024 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Oncolytic Virus Therapy Market Size Clinical Trials Sales Forecast 2030
May 14, 2024 01:08 ET
|
KuicK Research
Delhi, May 14, 2024 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights: Global Oncolytic Virus Immunotherapy Therapy...
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
April 09, 2024 12:00 ET
|
Imugene Limited
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
October 26, 2023 09:00 ET
|
Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...
Global Oncolytic Virus Therapies Market Size to Reach USD 1,546.51 Million in 2032 | Emergen Research
October 23, 2023 09:00 ET
|
Emergen Research
Vancouver, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The global oncolytic virus therapies market size is expected to reach USD 1,546.51 Million at a steady CAGR of 26.2% in 2032, according to latest...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 07, 2023 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
July 10, 2023 07:00 ET
|
Genelux Corporation
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented...